Beijing Aosaikang Pharmaceutical (002755.SZ): Injection of Delasaxin Cationic Amine Obtains Drug Registration Certificate

Beijing Aosaikang Pharmaceutical (002755.SZ) announced that its wholly-owned subsidiary Jiangsu Beijing Aosaikang Pharmaceutical Co., Ltd. (hereinafter referred to as the "subsidiary") recently received the "Drug Registration Certificate" for injection of Delafloxacin Tosylate and Delafloxacin Methanesulfonate issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). Delafloxacin is a new broad-spectrum antibiotic that exhibits a wide and powerful antibacterial activity against Gram-positive bacteria (G+), Gram-negative bacteria (G-), and anaerobic bacteria. Compared to other fluoroquinolone antibiotics, Delafloxacin has an anionic property that enhances its antibacterial activity in acidic environments. The drug accumulation in acidic environments can be ten times greater than other fluoroquinolone antibiotics, resulting in stronger antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and other pathogens. Delafloxacin has a novel structural feature that significantly enhances its antibacterial activity and reduces the likelihood of resistance. Its clinical efficacy and safety have been verified in both domestic and international clinical research, making it the only fluoroquinolone antibiotic recommended for MRSA treatment in the "Management Guidelines for Complicated Skin and Soft Tissue Infections" by the Surgical Infection Society (SIS), distinguishing it from traditional fluoroquinolone antibiotics which are not recommended for MRSA infections. It has good safety profile, with no reports of commonly seen risks associated with traditional fluoroquinolone antibiotics such as QT interval prolongation or phototoxicity.